[治疗糖尿病勃起功能障碍的和激活血液疗法:系统性审查和元分析]
Mao-Ke Chen1, Ke-Cheng Li1, Jun-Long Feng1
1Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Zhonghua nan ke xue = National journal of andrology
|September 18, 2025
概括
调脏和激活血疗法对治疗糖尿病勃起功能障碍有希望,显著改善IIEF-5得分和整体有效性. 需要进一步的高质量研究来证实这些关于糖尿病勃起功能障碍治疗的发现.
科学领域:
- 整合和补充医学是整合和补充医学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病性勃起功能障碍 (DMED) 是糖尿病的常见并发症.
- 目前对DMED的治疗方法有局限性和潜在的副作用.
- 传统中国医学,包括脏调和激活血疗法,正在探索DMED.
研究的目的:
- 系统地评估Tonifying脏和激活血液治疗DMED的临床疗效和安全性.
- 对这种治疗方法进行随机对照试验 (RCT) 的综合证据.
主要方法:
- 在多个数据库 (CNKI,Wanfang,VIP,CBM,PubMed,Cochrane,Embase,Web of Science) 进行了全面的文献搜索,直到2024年10月.
- 在查和质量评估后,包括了19个涉及1,612名患者的RCT.
- 使用RevMan 5.4进行了元分析,以评估国际勃起功能指数-5 (IIEF-5) 评分,总有效率和不良反应.
主要成果:
- 调整脏和激活血液疗法显著改善了IIEF-5评分 (MD=3.59,P<0.01) 和总有效率 (OR=4.30,P<0.00001).
- 在治疗组和对照组之间没有观察到不良反应发生率的统计学上显著差异 (OR=0.98,P=0.96).
- 分析表明,对治疗益处有很高的证据.
结论:
- 调脏和激活血疗法在改善糖尿病性勃起功能障碍患者的临床结果和IIEF-5分数方面是有效的.
- 该疗法似乎是安全的,与对照组相比,不良事件没有显著增加.
- 建议进行更多高质量的RCT来进一步验证这些发现,因为包括的研究数量有限.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
567
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
567
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Chronic Kidney Disease III: Interprofessional Care
344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
Antihypertensive Drugs: Action of Diuretics
2.2K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868

